Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076173 | 0.91 | PRKCQ (0.36) | PRKCQPRKCD | |
| SCHEMBL173166 | 0.86 | PRKCQ (0.35) | PRKCQPRKCD | |
| SCHEMBL669880 | 0.85 | RAF1 (0.36) | RAF1 | |
| SCHEMBL101590 | 0.84 | IRAK4 (0.38) | RAF1 | |
| SCHEMBL173106 | 0.84 | RAF1 (0.45) | RAF1 | |
| SCHEMBL1960222 | 0.81 | RAF1 (0.34) | PRKCQPRKCDRAF1 | |
| SCHEMBL1960225 | 0.81 | RAF1 (0.34) | PRKCQPRKCDRAF1 | |
| SCHEMBL669498 | 0.80 | NR1I2 (0.34) | RAF1 | |
| SCHEMBL102080 | 0.80 | CHEK1 (0.42) | RAF1 | |
| SCHEMBL12446818 | 0.79 | PRKCQ (0.37) | PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104674-B1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2013-05-01 | — | — | EP | claimed |
| EP-2559692-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | claimed |
| EP-2559691-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | claimed |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-11-29 | — | — | US | claimed |
| US-8269014-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-09-18 | — | — | US | claimed |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals ( Canada) Incorporated (CA) | 2012-03-08 | — | — | US | claimed |
| EP-2104674-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2009-09-30 | — | — | EP | claimed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | claimed |
| WO-2008058393-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2008-05-22 | — | — | WO | claimed |
| US-8658674-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658674-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658674-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2104674-B1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559692-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | disclosed |
| US-8003685-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2011-08-23 | — | — | US | disclosed |
| EP-2104674-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2009-09-30 | — | — | EP | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
| WO-2008058393-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | PRKCQ 4722/4885PRKCD 4774/4885RAF1 1444/4885 |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | PRKCQ 4722/4885PRKCD 4774/4885RAF1 1444/4885 |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | TTR, ZC3HAV1, IRF3 | PRKCQ 4722/4885PRKCD 4774/4885RAF1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.